真实世界银屑病关节炎队列中复杂管理、难治及治疗抵抗的频率:应用2025 GRAPPA与EULAR定义
在荷兰西南早期银屑病关节炎队列885例新诊断、未使用改善病情抗风湿药的患者中,20%符合GRAPPA复杂管理定义,4.2%符合EULAR难治定义,3.8%符合EULAR治疗抵抗,1.2%符合GRAPPA治疗抵抗。女性、较高BMI、较长症状持续时间、附着点炎和更广泛皮肤受累与符合定义相关,这些亚组患者长期报告更差的患者报告结局。
要点
- 约20%早期PsA符合GRAPPA复杂管理定义,为最早且最宽泛的亚组。
- 仅4.2%符合EULAR难治、3.8%符合EULAR治疗抵抗、1.2%符合GRAPPA治疗抵抗定义。
- 符合定义者女性更多、BMI更高、皮肤受累更广、附着点炎更多且长期PROs更差。
核心结论
- 约20%早期PsA符合GRAPPA复杂管理定义,4%符合EULAR难治/治疗抵抗,1.2%符合GRAPPA治疗抵抗。
- 后述亚组更可能为女性、较高BMI、更广泛皮肤受累和附着点炎,且长期PROs持续更差。
研究设计与样本
- 分析荷兰西南早期银屑病关节炎队列2013至2023年新诊断、未使用改善病情抗风湿药的PsA患者数据。
- 使用2025 GRAPPA(复杂管理、治疗抵抗)和EULAR(难治、治疗抵抗)PsA定义对患者分类。
- 采用Kaplan-Meier法进行时间至事件分析评估定义及组分满足时机,线性混合效应模型评估PROs纵向差异。
主要发现
- 885例新诊断PsA中,20%(179/885)符合GRAPPA复杂管理定义。
- 4.2%(37/885)符合EULAR难治定义,3.8%(34/885)符合EULAR治疗抵抗定义,1.2%(11/885)符合GRAPPA治疗抵抗定义。
- 女性、较高BMI、较长症状持续时间、附着点炎和更广泛皮肤受累在基线时与符合定义存在差异。
- GRAPPA复杂管理、GRAPPA治疗抵抗、EULAR难治和EULAR治疗抵抗患者长期报告更差PROs(HAQ-DI评分β=0.17,95%CI 0.10至0.24;β=0.37,95%CI 0.22至0.51;β=0.36,95%CI 0.20至0.48;β=0.40,95%CI 0.25至0.55)。
关键数值与推荐
- GRAPPA复杂管理定义:20%(179/885)符合。
- EULAR难治定义:4.2%(37/885)符合。
- EULAR治疗抵抗定义:3.8%(34/885)符合。
- GRAPPA治疗抵抗定义:1.2%(11/885)符合。
- HAQ-DI评分β值:GRAPPA复杂管理0.17(95%CI 0.10至0.24),GRAPPA治疗抵抗0.37(95%CI 0.22至0.51),EULAR难治0.36(95%CI 0.20至0.48),EULAR治疗抵抗0.40(95%CI 0.25至0.55)。
临床怎么用
- 早期PsA中约20%符合GRAPPA复杂管理定义,应识别该宽泛亚组并给予针对性管理。
- 符合EULAR难治/治疗抵抗或GRAPPA治疗抵抗定义者比例低但长期PROs更差,需更积极或 tailored 管理策略。
- 女性、较高BMI、较长症状持续时间、附着点炎和更广泛皮肤受累者更可能符合难治定义,临床应关注。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions. METHODS: We analysed data from newly diagnosed, disease-modifying antirheumatic drug-naïve patients with PsA enrolled in the Dutch Southwest Early Psoriatic Arthritis cohort between 2013 and 2023. Patients were classified using the 2025 GRAPPA (C2M, TR) and EULAR (D2M, TR) PsA definitions. Frequencies were calculated for each definition. Time-to-event analyses using Kaplan-Meier methods assessed the timing of definition fulfilment and individual components. Longitudinal differences in patient-reported outcomes (PROs) were assessed using linear mixed-effects models. RESULTS: Among 885 newly diagnosed patients with PsA, 20% (179/885) fulfilled the GRAPPA-C2M definition, 4.2% (37/885) fulfilled the EULAR-D2M definition, 3.8% (34/885) met the EULAR-TR and 1.2% (11/885) fulfilled the GRAPPA-TR criteria definition during follow-up. Female sex, higher body mass index (BMI), longer symptom duration, presence of enthesitis and greater skin involvement differed with meeting definitions at baseline. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M and EULAR-TR consistently reported worse long-term PROs (Health Assessment Questionnaire-Disability Index scores in C2M (β=0.17, 95% CI 0.10 to 0.24), GRAPPA-TR (β=0.37, 95% CI 0.22 to 0.51), EULAR-D2M (β=0.36, 95% CI 0.20 to 0.48) and EULAR-TR (β=0.40, 95% CI 0.25 to 0.55)). CONCLUSIONS: Approximately 20% of patients with early PsA fulfilled the GRAPPA-C2M criteria, representing the earliest and broadest subgroup, while 4% met EULAR-D2M/EULAR-TR and 1.2% GRAPPA-TR definitions. These latter subgroups were more likely to be female, had higher BMI, greater skin involvement and enthesitis and experienced persistently worse PROs, underscoring the need for tailored management strategies.
引用
- Koc GH, Kok MR, Snoeck Henkemans SVJ, et al. Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort. RMD Open. 2026. PMID: 42336609. doi:10.1136/rmdopen-2026-006783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。